Investigational drug · Phase 2
vilobelimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
12
Any phase or sponsor naming "vilobelimab"
First trial start
2025
Jun 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "vilobelimab", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome (ARDS)
- ARDS
- ARDS (Acute Respiratory Distress Syndrome)
- Acute Respiratory Distress Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "vilobelimab" as an intervention, largest first.
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)Pivotal-lookingRecruiting
PPD Development, LPIndustry
NCT06703073 · 600 participants (planned) · Start Jun 10, 2025 · Primary completion Jul 2028
Drug: Cohort A: vilobelimab; Cohort A: placebo and 4 more · For: Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome) and 1 more
Sites: Birmingham, Alabama; Fresno, California; Long Beach, California · 41 sites in all
- Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 PneumoniaPivotal-lookingCompleted
InflaRx GmbHIndustry
NCT04333420 · 399 participants · Start Mar 31, 2020 · Primary completion Oct 31, 2021
Drug: IFX-1 + BSC; BSC and 2 more · For: Severe COVID-19 Pneumonia
Sites: Aalst, Belgium; Brussels, Belgium; Leuven, Belgium · 48 sites in all
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: VilobelimabPivotal-lookingRecruiting
PPD Development, LPIndustry
NCT06701682 · 200 participants (planned) · Start Jun 21, 2025 · Primary completion Jul 2028
Drug: Cohort A: vilobelimab; Cohort A: placebo · For: Acute Respiratory Distress Syndrome (ARDS); ARDS; ARDS (Acute Respiratory Distress Syndrome) and 1 more
Sites: Birmingham, Alabama; Fresno, California; Long Beach, California · 41 sites in all
- Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)Pivotal-lookingCompleted
InflaRx GmbHIndustry
NCT03487276 · 179 participants · Start Feb 26, 2018 · Primary completion May 27, 2019
Drug: IFX-1; Placebo · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Fort Myers, Florida; Miami, Florida · 41 sites in all
- Studying Complement Inhibition in Complex Cardiac SurgeryPivotal-lookingCompleted
InflaRx GmbHIndustry
NCT02866825 · 116 participants · Start May 2016 · Primary completion Dec 2016
Drug: IFX-1; Placebo · For: Systemic Inflammatory Response Syndrome; C.Surgical Procedure; Cardiac
Sites: Aachen, Germany; Dortmund, Germany; Dresden, Germany · 10 sites in all
InflaRx GmbHIndustry
NCT02246595 · 72 participants · Start Apr 2014 · Primary completion Dec 2015
Drug: CaCP29; Placebo · For: Severe Sepsis; Septic Shock
Sites: Aachen, Germany; Augsburg, Germany; Bad Saarow, Germany · 11 sites in all
InflaRx GmbHIndustry
NCT03895801 · 57 participants · Start Apr 3, 2019 · Primary completion Apr 14, 2021
Drug: IFX-1; Placebo-IFX-1 and 2 more · For: Granulomatosis With Polyangiitis (GPA); Microscopic Polyangiitis (MPA)
Sites: Leuven, Belgium; Liège, Belgium; Hradec Králové, Czechia · 76 sites in all
- Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma GangrenosumPivotal-lookingTerminated
InflaRx GmbHIndustry
NCT05964413 · 54 participants · Start Nov 1, 2023 · Primary completion Jul 11, 2025
Drug: vilobelimab; Placebo · For: Pyoderma Gangrenosum
Sites: Hialeah, Florida; Miami, Florida; Orlando, Florida · 50 sites in all
InflaRx GmbHIndustry
NCT04812535 · 30 participants · Start Mar 31, 2021 · Primary completion Jun 4, 2024
Drug: Vilobelimab; Vilobelimab + pembrolizumab combination therapy · For: SCC - Squamous Cell Carcinoma of Skin
Sites: La Jolla, California; Aurora, Colorado; Miami, Florida · 25 sites in all
InflaRx GmbHIndustry
NCT03712345 · 20 participants · Start Oct 15, 2018 · Primary completion Sep 10, 2020
Drug: IFX-1 low dose; IFX-1 high dose and 1 more · For: Granulomatosis With Polyangiitis (GPA); Microscopic Polyangiitis (MPA)
Sites: Scottsdale, Arizona; Loma Linda, California; Doral, Florida · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic Approaches to Treat SARS-CoV-2.
Sharma L, Maheshwari N, Maheshwari N, et al. · ChemMedChem 2026
- Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial.
Giamarellos-Bourboulis EJ, Jemec GBE, Prens EP, et al. · Br J Dermatol 2026
- The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study.
Malone DC, Seheult R, Brixner D, et al. · Am J Health Syst Pharm 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness.
Bhimraj A, Falck-Ytter Y, Baden LR, et al. · Clin Infect Dis 2026
- 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab.
Nadig N, Bhimraj A, Cawcutt K, et al. · Clin Infect Dis 2026
- Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis.
Chau KWT, Thet Z, Gardner LS, et al. · Clin Exp Nephrol 2025
Also in development for Acute Respiratory Distress Syndrome (ARDS)
- CenthaquinePMZ-2010Phase 32 trials
Pharmazz, Inc. · Acute Respiratory Distress Syndrome (ARDS), Hypovolemic Shock
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- ALT-100Phase 21 trial
Aqualung Therapeutics Corp. · Acute Respiratory Distress Syndrome (ARDS)
- TISA-818-InjPhase 21 trial
EnliTISA (Shanghai) Pharmaceutical Co., Ltd. · Acute Respiratory Distress Syndrome (ARDS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.